欧洲前列腺癌筛查随机研究16年随访结果
该多中心人群随机筛查试验纳入182160名男性,核心年龄组162389名55-69岁男性,随访至2014年(最长16年)。16年时前列腺癌死亡率的率比为0.80(95%CI 0.72-0.89,p<0.001),绝对死亡率差异从13年的0.14%增至16年的0.18%,需邀请筛查人数从742降至570,需诊断人数从26降至18。结论证实PSA筛查显著降低前列腺癌死亡率,随访越长绝对获益越大,重复筛查对降低人群前列腺癌死亡率可能重要。
要点
- 16年随访时PSA筛查使前列腺癌死亡率率比为0.80(95%CI 0.72-0.89,p<0.001)。
- 绝对死亡率差异从13年的0.14%增至16年的0.18%,需邀请筛查人数从742降至570。
- 第一轮检出者PSA>20ng/ml比例9.9%高于第二轮4.1%(p<0.001),死亡风险HR=1.86(p<0.001)。
核心结论
- 研究结果证实PSA筛查显著降低前列腺癌死亡率,随访更长时绝对获益更大且超额发病率降低。
- 作者认为重复筛查对降低人群水平的前列腺癌死亡率可能重要。
研究设计与样本
- 欧洲前列腺癌筛查随机研究(ERSPC)为八国多中心人群随机筛查试验,报告纳入182160名男性,随访至2014年(最长16年),预设核心年龄组为162389名55-69岁男性,选自人口登记。
- 分析结果时对未参与率和参与筛查轮数进行了校正。
主要发现
- 16年时前列腺癌死亡率率比为0.80(95%CI 0.72-0.89,p<0.001)。
- 绝对前列腺癌死亡率差异从13年的0.14%增至16年的0.18%。
- 16年时需邀请筛查以预防一例前列腺癌死亡的人数为570,13年时为742。
- 需诊断人数从13年的26降至18。
- 第一轮检出的前列腺癌患者中PSA>20ng/ml的患病率为9.9%,第二轮为4.1%(p<0.001);第一轮检出者前列腺癌死亡风险HR=1.86(p<0.001),高于后续检出者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality. OBJECTIVE: To determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended. DESIGN, SETTING, AND PARTICIPANTS: This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182160 men, followed up until 2014 (maximum of 16yr), with a predefined core age group of 162389 men (55-69yr), selected from population registry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended. RESULTS AND LIMITATIONS: The rate ratio of PCa mortality was 0.80 (95% confidence interval [CI] 0.72-0.89, p<0.001) at 16yr. The difference in absolute PCa mortality increased from 0.14% at 13yr to 0.18% at 16yr. The number of men needed to be invited for screening to prevent one PCa death was 570 at 16yr compared with 742 at 13yr. The number needed to diagnose was reduced to 18 from 26 at 13yr. Men with PCa detected during the first round had a higher prevalence of PSA >20ng/ml (9.9% compared with 4.1% in the second round, p<0.001) and higher PCa mortality (hazard ratio=1.86, p<0.001) than those detected subsequently. CONCLUSIONS: Findings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level. PATIENT SUMMARY: In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.
引用
- Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019. PMID: 30824296. doi:10.1016/j.eururo.2019.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。